ELF-1 expression in nasopharyngeal carcinoma facilitates proliferation and metastasis of cancer cells via modulation of CCL2/CCR2 signaling

References

• Bei JX, Li Y, Jia WH, et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010;42(7):599–603. doi:10.1038/ng.60120512145
   PubMed Web of Science ®Google Scholar
• Zhao YY, Tian Y, Liu L, et al. Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma. Drug Des Devel Ther. 2018;12:2655–2663. doi:10.2147/DDDT.S169952
   PubMed Web of Science ®Google Scholar
• Shen Y, Zhang S, Sun R, Wu T, Qian J. Understanding the interplay between host immunity and Epstein-barr virus in NPC patients. Emerg Microbes Infect. 2015;4(3):e20. doi:10.1038/emi.2015.2026038769
   PubMedGoogle Scholar
• Lee AW, Ma BB, Ng WT, Chan AT. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol. 2015;33(29):3356–3364. doi:10.1200/JCO.2015.60.934726351355
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388(10054):1883–1892. doi:10.1016/S0140-6736(16)31388-527567279
   PubMed Web of Science ®Google Scholar
• Zhang P, Hong H, Sun X, et al. MicroRNA-10b regulates epithelial-mesenchymal transition by modulating KLF4/Notch1/E-cadherin in cisplatin-resistant nasopharyngeal carcinoma cells. Am J Cancer Res. 2016;6(2):141–156. 27186392
   PubMed Web of Science ®Google Scholar
• Degnan BM, Degnan SM, Naganuma T, Morse DE. The ets multigene family is conserved throughout the metazoa. Nucleic Acids Res. 1993;21(15):3479–3484. 8346026
   PubMed Web of Science ®Google Scholar
• Poon GMK, Kim HM. Signatures of DNA target selectivity by ETS transcription factors. Transcription. 2017;8(3):193–203. doi:10.1080/21541264.2017.130290128301293
   PubMed Web of Science ®Google Scholar
• Findlay VJ, LaRue AC, Turner DP, Watson PM, Watson DK. Understanding the role of ETS-mediated gene regulation in complex biological processes. Adv Cancer Res. 2013;119:1–61. doi:10.1016/B978-0-12-407190-2.00001-023870508
   PubMed Web of Science ®Google Scholar
• Sizemore GM, Pitarresi JR, Balakrishnan S, Ostrowski MC. The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer. 2017;17(6):337–351. doi:10.1038/nrc.2017.2028450705
   PubMed Web of Science ®Google Scholar
• Yang DX, Li NE, Ma Y, Han YC, Shi Y. Expression of Elf-1 and survivin in non-small cell lung cancer and their relationship to intratumoral microvessel density. Chin J Cancer. 2010;29(4):396–402. 20346215
   PubMedGoogle Scholar
• Calero-Nieto FJ, Wood AD, Wilson NK, Kinston S, Landry JR, Gottgens B. Transcriptional regulation of Elf-1: locus-wide analysis reveals four distinct promoters, a tissue-specific enhancer, control by PU.1 and the importance of Elf-1 downregulation for erythroid maturation. Nucleic Acids Res. 2010;38(19):6363–6374. doi:10.1093/nar/gkq49020525788
   PubMed Web of Science ®Google Scholar
• Walunas TL, Wang B, Wang CR, Leiden JM. Cutting edge: the Ets1 transcription factor is required for the development of NK T cells in mice. J Immunol. 2000;164(6):2857–2860. 10706669
   PubMed Web of Science ®Google Scholar
• Choi HJ, Geng Y, Cho H, et al. Differential requirements for the Ets transcription factor Elf-1 in the development of NKT cells and NK cells. Blood. 2011;117(6):1880–1887. doi:10.1182/blood-2010-09-30946821148815
   PubMed Web of Science ®Google Scholar
• Gerloff A, Dittmer A, Oerlecke I, Holzhausen HJ, Dittmer J. Protein expression of the Ets transcription factor Elf-1 in breast cancer cells is negatively correlated with histological grading, but not with clinical outcome. Oncol Rep. 2011;26(5):1121–1125. doi:10.3892/or.2011.140921811762
   PubMed Web of Science ®Google Scholar
• Takai N, Miyazaki T, Nishida M, Shang S, Nasu K, Miyakawa I. Clinical relevance of Elf-1 overexpression in endometrial carcinoma. Gynecol Oncol. 2003;89(3):408–413. 12798703
   PubMed Web of Science ®Google Scholar
• Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I. The significance of Elf-1 expression in epithelial ovarian carcinoma. Int J Mol Med. 2003;12(3):349–354. 12883651
   PubMed Web of Science ®Google Scholar
• Huang X, Brown C, Ni W, Maynard E, Rigby AC, Oettgen P. Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis. Blood. 2006;107(8):3153–3160. doi:10.1182/blood-2005-08-320616352813
   PubMed Web of Science ®Google Scholar
• Han R, Gu S, Zhang Y, et al. Estrogen promotes progression of hormone-dependent breast cancer through CCL2-CCR2 axis by upregulation of Twist via PI3K/AKT/NF-kappaB signaling. Sci Rep. 2018;8(1):9575. doi:10.1038/s41598-018-27810-629934505
   PubMedGoogle Scholar
• Hong KH, Ryu J, Han KH. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood. 2005;105(4):1405–1407. doi:10.1182/blood-2004-08-317815498848
   PubMed Web of Science ®Google Scholar
• Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst. 2010;102(8):522–528. doi:10.1093/jnci/djq04420233997
   PubMedGoogle Scholar
• Takai N, Ueda T, Nishida M, Nasu K, Miyakawa I. The relationship between oncogene expression and clinical outcome in endometrial carcinoma. Curr Cancer Drug Targets. 2004;4(6):511–520. 15379636
   PubMed Web of Science ®Google Scholar
• Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene. 2003;303:11–34. 12559563
   PubMed Web of Science ®Google Scholar
• Xiang P, Lo C, Argiropoulos B, et al. Identification of E74-like factor 1 (ELF1) as a transcriptional regulator of the Hox cofactor MEIS1. Exp Hematol. 2010;38(9):798–798, 808 e791-792. doi:10.1016/j.exphem.2010.06.006
   Web of Science ®Google Scholar
• Jin E, Liu J, Suehiro J, et al. Differential roles for ETS, CREB, and EGR binding sites in mediating VEGF receptor 1 expression in vivo. Blood. 2009;114(27):5557–5566. doi:10.1182/blood-2009-05-22043419822898
   PubMed Web of Science ®Google Scholar
• Iljin K, Dube A, Kontusaari S, et al. Role of ets factors in the activity and endothelial cell specificity of the mouse Tie gene promoter. FASEB J. 1999;13(2):377–386. 9973326
   PubMed Web of Science ®Google Scholar
• Seth A, Watson DK, Blair DG, Papas TS. c-ets-2 protooncogene has mitogenic and oncogenic activity. Proc Natl Acad Sci U S A. 1989;86(20):7833–7837. 2813360
   PubMed Web of Science ®Google Scholar
• Leiden JM, Wang CY, Petryniak B, Markovitz DM, Nabel GJ, Thompson CB. A novel Ets-related transcription factor, Elf-1, binds to human immunodeficiency virus type 2 regulatory elements that are required for inducible trans activation in T cells. J Virol. 1992;66(10):5890–5897. 1527846
   PubMed Web of Science ®Google Scholar
• Juang YT, Tenbrock K, Nambiar MP, Gourley MF, Tsokos GC. Defective production of functional 98-kDa form of Elf-1 is responsible for the decreased expression of TCR zeta-chain in patients with systemic lupus erythematosus. J Immunol. 2002;169(10):6048–6055. 12421992
   PubMed Web of Science ®Google Scholar
• Dube A, Thai S, Gaspar J, et al. Elf-1 is a transcriptional regulator of the Tie2 gene during vascular development. Circ Res. 2001;88(2):237–244. 11157678
   PubMed Web of Science ®Google Scholar
• Hegen A, Koidl S, Weindel K, Marme D, Augustin HG, Fiedler U. Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements. Arterioscler Thromb Vasc Biol. 2004;24(10):1803–1809. doi:10.1161/01.ATV.0000140819.81839.0e15284088
   PubMed Web of Science ®Google Scholar
• Pimanda JE, Chan WY, Donaldson IJ, Bowen M, Green AR, Gottgens B. Endoglin expression in the endothelium is regulated by Fli-1, Erg, and Elf-1 acting on the promoter and a −8-kb enhancer. Blood. 2006;107(12):4737–4745. doi:10.1182/blood-2005-12-492916484587
   PubMed Web of Science ®Google Scholar
• Andrews PG, Kennedy MW, Popadiuk CM, Kao KR. Oncogenic activation of the human Pygopus2 promoter by E74-like factor-1. Mol Cancer Res. 2008;6(2):259–266. doi:10.1158/1541-7786.MCR-07-006818314487
   PubMed Web of Science ®Google Scholar
• Tzenov YR, Andrews PG, Voisey K, et al. Human papilloma virus (HPV) E7-mediated attenuation of retinoblastoma (Rb) induces hPygopus2 expression via Elf-1 in cervical cancer. Mol Cancer Res. 2013;11(1):19–30. doi:10.1158/1541-7786.MCR-12-051023284001
   PubMed Web of Science ®Google Scholar
• Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313–326. doi:10.1089/jir.2008.002719441883
   PubMed Web of Science ®Google Scholar
• Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget. 2016;7(19):28697–28710. doi:10.18632/oncotarget.737626885690
   PubMedGoogle Scholar
• O‘Connor T, Borsig L, Heikenwalder M. CCL2-CCR2 signaling in disease pathogenesis. Endocr Metab Immune Disord Drug Targets. 2015;15(2):105–118. 25772168
   PubMed Web of Science ®Google Scholar
• Zhang T, Somasundaram R, Berencsi K, et al. Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur J Immunol. 2006;36(2):457–467. doi:10.1002/eji.20052620816421945
   PubMed Web of Science ®Google Scholar
• Tang CH, Tsai CC. CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-kappaB signaling pathway. Biochem Pharmacol. 2012;83(3):335–344. doi:10.1016/j.bcp.2011.11.01322138288
   PubMed Web of Science ®Google Scholar